Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

— Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration.

— These results support the further clinical development of INNA-051 to mitigate the impact of natural infection by respiratory viruses such as SARS-CoV-2 and its variants: influenza, RSV, and the common cold, in individuals at risk of more severe illness.

MELBOURNE, Australia, Feb. 14, 2023 (GLOBE NEWSWIRE) — ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of respiratory viral infections, was found to significantly impact the course of viral infection in a Phase 2a flu challenge study.

The study included 123 adults (ages 19 to 53) randomized to receive two doses of INNA-051 (low and high dose) or placebo, then challenged with a substantial dose of H3N2 influenza A virus. The viral inoculum was expected to result in a large majority of participants being infected. Interpretation of the study was complicated by lower than anticipated rates of infection in the placebo arm and an unexpectedly large proportion of participants having pre-existing immunity to the challenge strain across all groups (assessed using the hemagglutination inhibition assay). Post hoc analyses excluding those with pre-existing immunity showed that INNA-051-treated participants with PCR laboratory-confirmed infection had a statistically significant shorter duration of infection. This effect was greater with the higher dose. Although not statistically significant, a dose-related reduction in the duration of symptoms was also observed.

Notably, the study confirmed the safety profile of INNA-051. Compared with the placebo group, participants receiving INNA-051 showed no increase in the incidence, magnitude, or duration of any flu symptom, nor enhanced local or systemic signs or symptoms associated with the viral challenge. The most common adverse events associated with the study medication were mild, short-lived and similar to those observed during the initial Phase 1 study.

“This study further supports the concept that boosting the local innate immune response to common respiratory viruses has potential clinical benefit. In this study, INNA-051 was found to be safe and to significantly impact the course of infection. We are eager to investigate INNA-051’s clinical benefit in the context of natural viral respiratory tract infections in individuals at increased risk of more severe illness,” said Christophe Demaison PhD, Managing Director and CEO of ENA Respiratory.

Earlier research in humans and animals has shown that INNA-051 activates the innate immune system in the nose, a common site of infection. These Phase 2a study results mirror those seen in animal respiratory infection models, and are consistent with the INNA-051 mechanism of action. INNA-051 accelerates virus clearance and reduces virus spread to other parts of the body. It is anticipated that INNA-051 prophylaxis will reduce illness severity and healthcare utilization in individuals exposed to respiratory viral infections, especially in those at high risk of complications.

“Many people around the world have now been impacted by a ‘tripledemic’ of flu, RSV and SARS-Cov-2 viruses that have been circulating together in recent months. The surge in illness and hospitalization demonstrates the urgent need for a broad-spectrum treatment to boost immunity against common respiratory illnesses, and these data suggest INNA-051 is a promising option,” said Scott White MD, Chief Medical Officer, ENA Respiratory.

Notes to Editors

If you would like to arrange an interview, please contact:

About ENA Respiratory and INNA-051

ENA Respiratory aims to transform the prevention of respiratory viral infections in populations at-risk of complications. The company is based in Melbourne and Sydney, Australia, and it has secured a Series A investment from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

INNA-051 is a potent innate immune TLR2/6 agonist. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. It is being developed for intranasal delivery to target the primary entry site of viral respiratory infections, as most respiratory viruses, including SARS-CoV-2 and influenza, initially infect and replicate in nasal mucosa epithelial cells. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

Key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

For more information, please visit

GlobeNewswire Distribution ID 8746674

Fresh Produce Distributor Jacques Remy & Sons Using Descartes’ Route Planning Solution to Reduce Transportation Costs and Improve Service

ATLANTA and PARIS, Feb. 13, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Jacques Remy & Sons, a leading Belgian distributor of fresh produce, has optimized its multi-country distribution operations with Descartes’ route planning solution. Deployed in less than two months, the cloud-based solution reduced the distributor’s transportation costs, enabled real-time delivery tracking to enhance the customer experience, and ensured the company could efficiently and cost-effectively manage the upswing in sales activity.

“Given an influx of new contracts and the logistical complexities and regulatory constraints of transporting fresh produce to multiple countries, we needed to optimize delivery performance and tracking in order to meet customer expectations,” said Isabelle Libert, Executive Assistant at Jacques Remy & Sons. “The rapid implementation of the routing solution, coupled with Descartes’ change management expertise, enabled us to immediately reap the operational and bottom-line benefits across our combined fleet of vans and transport trucks that deliver to both grocery stores and wholesalers as well as to small business professionals.”

Part of Descartes’ route planning and execution, mobile and telematics suite, Descartes’ route planning and optimization helps brands achieve more agile, efficient and sustainable routing by generating additional delivery capacity and reducing costs. For distribution-intensive companies, like Jacques Remy & Sons, the solution creates delivery efficiencies and improves customer service by optimizing delivery routes and managing their execution through a real-time mobile application used by drivers. Drivers also use the mobile application to capture proof-of-delivery (POD) details. Real-time text or email notifications keep customers up to date with the progress of the delivery to enhance the customer experience.

“We’re pleased that our route planning solution has rapidly transformed delivery management into a differentiating element of Jacques Remy & Sons’ business strategy, making it a lever for customer satisfaction and loyalty,” said Peio Ribas, Senior Vice President Sales, EMENAR at Descartes. “Now that plan versus actual performance tracking is in place, they have the data to calculate the cost of each delivery and vehicle. Our cloud-based route planning, execution, and mobile solution allows companies to consistently provide superior delivery performance while minimizing distribution costs as they scale and grow.”

For more information, visit Descartes’ Routing, Mobile and Telematics resource center.

About Jacques Remy & Sons

Founded in 1974 by the Remy family, Jacques Remy & Sons has distinguished itself by continually offering quality products at affordable prices and maintaining the strictest standards and certification requirements for the transportation of products to our customers. For more information, visit

About Descartes

Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at, and connect with us on LinkedIn and Twitter.

Global Media Contact
Cara Strohack                                                    
Tel: +1(800) 419-8495 ext. 202025               

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes’ most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

GlobeNewswire Distribution ID 8747199

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

London, U.K., Feb. 13, 2023 (GLOBE NEWSWIRE) — OPEN Health, a pre-eminent global provider of scientific communications and HEOR & market access services, announced the acquisition of Acsel Health (“Acsel”), a New York-based life science strategy and advisory firm focused on commercial strategy, pricing and market access, and commercial excellence.

Acsel’s deep industry expertise, scientific rigor, and actionable analysis drives its success in providing valued partnership to life science companies. These capabilities will complement OPEN Health’s existing offering, broadening the range of services it offers to pharma and biotech companies.

Lujing Wang, Managing Partner of Acsel Health, said, “We are thrilled to join OPEN Health and to work with a wider team to solve for today’s demands and meet tomorrow’s expectations for pharma and biotech customers. With new colleagues and capabilities to partner with, we are equipped to answer the most challenging cross-disciplinary questions in life science across all key therapeutic areas.”

“Acsel is an extraordinary addition to OPEN Health. Acsel’s expert team and long-standing client relationships significantly strengthen our ability to support the commercialization of our clients’ assets and unlock access for patients.” said OPEN Health CEO, Rob Barker. “We are excited to welcome Acsel Health into the OPEN Health Group and look forward to working with our new colleagues to offer our clients innovative, scientific solutions around the globe.”

Fairmount Partners acted as exclusive financial advisor to Acsel Health. The terms of the transaction were not disclosed.

About OPEN Health

OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient wellbeing. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across HEOR and market access, medical communications and creative omnichannel campaigns. For more information on OPEN Health, visit

About Acsel Health

Acsel Health is a consulting firm that partners with renowned life science companies to guide life-changing innovations through their critical stages, from early development through market maturity. Acsel applies best-practice principles to develop and deliver highly individualized solutions to challenges across the product lifecycle for our clients. For more information on Acsel Health, visit


Candice Subero
OPEN Health

GlobeNewswire Distribution ID 8744608

Sambo sentenced to death over premeditated murder of Brigadier J

The South Jakarta District Court has sentenced Ferdy Sambo to death for his role in the premeditated murder of Brigadier Nofriansyah Yosua Hutabarat, also known as Brigadier J, in July 2022.

At a trial session here on Monday, Chief Judge Wahyu Iman Santoso said that Sambo has been proven to have violated Article 340 subsidiary Article 338 in conjunction with Article 55 Paragraph (1) Number 1 of the Criminal Code.

Sambo also violated Article 49 in conjunction with Article 33 of Law No. 19 of 2016 on Changes to Law No. 11 of 2008 on Electronic Information and Transaction, in conjunction with Article 55 Paragraph (1) Number 1 of the Criminal Code, the judge added.

Based on this consideration, Santoso said that the judges do not have sufficient confidence that Hutabarat perpetrated sexual violence against Putri Candrawathi, Sambo’s wife—the reason that Sambo had cited as justification for the murder.

Moreover, the judge informed that they had sufficient confidence that Sambo’s action constituted a premeditated murder.

Santoso cited Sambo’s misguided behavior in relation to his position as a high-ranking officer in the Indonesian Police as an aggravating factor in deciding the death sentence for the defendant.

“The defendant’s action has dragged a large number of police officers (into the crime),” the judge stated.

The judge’s decision to sentence Sambo to death was harsher than the life sentence sought by prosecutors at an earlier trial session on January 17, 2023.

Sambo was one of the five defendants in the premeditated murder of Brigadier J. The other defendants are Ricky Rizal, Richard Eliezer, Putri Candrawathi, and Kuat Ma’ruf.

The five defendants were charged with violating Article 340, subsidiary Article 338 in conjunction with Article 55 paragraph (1) Number 1 of the Criminal Code.

In two trial sessions on January 16, prosecutors sought eight years in prison for Candrawathi, Ma’ruf, and Rizal. Meanwhile, the prosecutors sought 12 years for Eliezer at a trial session on January 18.

Source: Antara News

Need to improve awareness, early detection of childhood cancer: MPR

Public knowledge of childhood cancer as well as early detection of the disease must be expedited to ensure the longevity of patients, deputy chairperson of the People’s Consultative Assembly Lestari Moerdijat has stressed.

“Knowledge and early detection of cancer in children must be improved in order to increase the life expectancy of patients. A healthy lifestyle must also be adopted from an early age so that children’s nutritional needs are fulfilled,” she said in a written statement received here on Monday.

Everyone must consistently collaborate in efforts to push for higher life expectancy of children diagnosed with cancer, she added.

Moerdijat referred to data from the National Association of Pediatrics (IDAI), which showed that in 2022, as many as 1,821 children were recorded as cancer patients and received treatment at 12 big hospitals in Indonesia.

Citing the data, she said that children can be at risk of contracting some types of cancer because of certain combinations of genes received from parents. However, if the disease is detected early and treated immediately, the life expectancy of patients can increase.

Hence, the data established by the association must be followed up with efforts from the public and the stakeholders to resolve the issue.

Moerdijat said that the number of child cancer patients, which almost reached two thousand in 2022, must become a matter of concern for everyone in the country so that actual efforts can be made to consistently bring down this number.

The government and the public must pursue good collaboration to develop an early detection system as a means to prevent the rampant growth of some diseases in kids, cancer included, she added.

People must also pay attention to some aspects of childhood cancer treatment, such as the number of medical staff as well as the quality of medical facilities.

Source: Antara News

Economic stagnation if imports exceed domestic products’ use: Nazara

Indonesia’s economy would not grow if the percentage of imports continued to be higher than the level of use of domestic products, Deputy Finance Minister Suahasil Nazara stated.

Nazara also cautioned that unrestricted imports might impede industrial and economic growth in Indonesia.

“Let this issue be a reflection for our working units or workplaces (to motivate them) to use domestic-made products,” Nazara said at the 2023 Series of PT PLN Leaders Talk seminar observed online here on Monday.

He noted that increasing the use of domestic-made products among residents is one of the most effective mediums to rev up Indonesia’s economic growth.

The use of domestic-made products is also a focus in the efforts to spur commodity downstreaming that had emerged as a new source of economic growth for the country, he pointed out.

The deputy minister emphasized that the downstreaming process, which the government advocates, aims to realize Indonesia as an advanced country that could escape the middle-income trap and achieve higher per capita income.

“All of those could not be achieved without the manufacture (sector’s role),” Nazara pointed out.

To realize downstreaming goals, the government has banned the export of some raw commodities, he noted while adding that the prohibition offered a legal basis to redirect raw commodities for domestic processing.

Apart from the domestic product use and downstreaming, Nazara stated that four other new economic growth sources are the digital economy; development of micro, small, and medium enterprises (MSMEs); development of green economy; and transition to renewable energies.

Indonesia has begun prohibiting the export of raw materials to increase its added value and promote industrial growth. Following the ban on nickel ore exports in 2020, the government decided to prohibit the export of bauxite raw materials starting from June 2023 as well as of raw copper, also in this year.

Source: Antara News

Zoo visitors must prepare for unexpected animal behavior: Uno

People visiting zoos need to be aware that they are entering the habitats of wild animals so they must be prepared in case the animals show unusual or unexpected behavior.

Tourism and Creative Economy Minister Sandiaga Salahuddin Uno made the remarks during the “Weekly Brief with Sandi Uno,” which was hosted here on Monday.

“We need to do adjustment because we are visiting their habitat. So, information needs to be extensively given on how to act should we encounter such situation,” the minister said.

He made the appeal following an incident at Prigen Zoo, East Java, in which two fighting lions struck the back of a visitor’s car.

The minister said that the incident was not out of the ordinary and would not negatively impact or compromise the number of visits to conservation-based vacation sites, such as the newly established zoo in Central Java, the Solo Safari.

The incident, which became a topic among netizens, occurred on February 11, 2023. According to reports, two fighting lions dashed toward a visitor’s car inside Prigen Safari Park in East Java during a chase, hitting its back and leaving a dent.

Following the incident, Taman Safari Indonesia Cisarua, Bogor district, West Java, issued a warning to visitors asking them not to stop their vehicles in the vicinity of wild animals.

“Vehicles may not stop when entering the domain of wild animals because the animals in the Safari Park are allowed to behave and roam freely,” the general manager of Taman Safari Indonesia, Emeraldo Parengkuan, said in a statement on Monday.

Source: Antara News